First Interstate Bank grew its stake in shares of Allergan plc (NYSE:AGN) by 58.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,063 shares of the company’s stock after purchasing an additional 1,495 shares during the period. First Interstate Bank’s holdings in Allergan were worth $665,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in AGN. Cable Hill Partners LLC lifted its position in Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after acquiring an additional 370 shares during the period. BB&T Investment Services Inc. lifted its position in Allergan by 1,308.2% during the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after acquiring an additional 641 shares during the period. Acropolis Investment Management LLC purchased a new position in Allergan during the 4th quarter valued at about $153,000. Zions Bancorporation lifted its position in Allergan by 1,115.6% during the 3rd quarter. Zions Bancorporation now owns 936 shares of the company’s stock valued at $192,000 after acquiring an additional 859 shares during the period. Finally, Field & Main Bank purchased a new position in Allergan in the fourth quarter worth about $155,000. 79.66% of the stock is currently owned by hedge funds and other institutional investors.
AGN has been the subject of several recent analyst reports. Cantor Fitzgerald set a $191.00 target price on shares of Allergan and gave the stock a “hold” rating in a report on Tuesday, December 12th. Vetr cut shares of Allergan from a “hold” rating to a “sell” rating and set a $180.97 target price for the company. in a report on Monday, January 22nd. Bank of America lifted their target price on shares of Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Deutsche Bank reaffirmed a “buy” rating and issued a $215.00 target price on shares of Allergan in a report on Tuesday, January 9th. Finally, ValuEngine cut shares of Allergan from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $225.94.
Shares of Allergan plc (AGN) opened at $159.91 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 1.06 and a debt-to-equity ratio of 0.38. The stock has a market cap of $54,753.90, a P/E ratio of 10.12, a P/E/G ratio of 1.17 and a beta of 1.19. Allergan plc has a 12-month low of $156.00 and a 12-month high of $256.80.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.74 by $0.12. The company had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the business posted $3.90 earnings per share. equities analysts predict that Allergan plc will post 15.58 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.80%. This is a positive change from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s payout ratio is -20.86%.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.